A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Cetrelimab (Primary) ; Gemcitabine (Primary)
- Indications Bladder cancer; Carcinoma; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms SunRISe-4
- Sponsors Janssen Research & Development; Janssen-Cilag
- 27 Feb 2024 Planned primary completion date changed from 29 Dec 2023 to 1 Dec 2026.
- 10 Oct 2023 Planned End Date changed from 17 Dec 2025 to 16 Mar 2027.
- 30 May 2023 Planned primary completion date changed from 10 Apr 2023 to 29 Dec 2023.